the modified medical research council dyspnea scale

MRC Dyspnoea Scale

The mMRC (Modified Medical Research Council) Dyspnoea Scale is used to assess the degree of baseline functional disability due to dyspnoea.

It is useful in characterising baseline dyspnoea in patients with respiratory disease such as COPD. Whilst it moderately correlates with other healthcare-associated morbidity, mortality and quality of life scales (particularly in COPD) the scores are only variably associated with patients' perceptions of respiratory symptom burden. It is used as a component of the BODE Index, which predicts adverse outcomes, including mortality and risk of hospitalisation. The scale is easy and efficient to use.

The mMRC breathlessness scale ranges from grade 0 to 4. It is very similar to the original version and is now widely used in studies. It should be noted that the MRC clearly states on its website that it is unable to give permission for use of any modified version of the scale (including therefore, the mMRC scale). Use of the MRC questionnaire is free but should be acknowledged.

The modified MRC was developed by D A Mahler, see  https://pubmed.ncbi.nlm.nih.gov/3342669/

Diagnostic testing

Your essential guide to respiratory diagnostic testing from FeNO and spirometry to CRP Point of Care Testing.

Clinical resources

Step by step guides, expert opinion, the latest insights and case studies - our resources cover a range of respiratory topics and a vital resource for any practitioner working in the delivery of respiratory healthcare

PCRS Respiratory Conference

The UK's leading respiratory conference for clinicians working primary, community and integrated care comes to Telford in September.

You may also be interested in...

Step by step guides, podcasts and webinars cover prevention, diagnosis, testing and management. They will help you to support your patients and improve their outcomes.

Inhaler devices

Inhaler devices may seem simple to use but they are often used incorrectly by patients and healthcare professionals alike.

Chronic Obstructive Pulmonary Disease (COPD) is the fifth leading cause of death in the UK. It's a serious condition which calls for a patient centric approach.

Join PCRS Today

Become part of the UK's largest network of dedicated respiratory professionals working in primary, community and integrated care settings.

• Type 2 Diabetes
• Heart Disease
• Digestive Health
• Multiple Sclerosis
• Diet & Nutrition
• Health Insurance
• Public Health
• Patient Rights
• Caregivers & Loved Ones
• End of Life Concerns
• Health News
• Thyroid Test Analyzer
• Doctor Discussion Guides
• Hemoglobin A1c Test Analyzer
• Lipid Test Analyzer
• Complete Blood Count (CBC) Analyzer
• What to Buy
• Editorial Process
• Meet Our Medical Expert Board

Measuring Shortness of Breath (Dyspnea) in COPD

How the Perception of Disability Directs Treatment

Dyspnea is the medical term used to describe shortness of breath, a symptom considered central to all forms of chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis.

As COPD is both a progressive and non-reversible, the severity of dyspnea plays a key role in determining both the stage of the disease and the appropriate medical treatment.

Challenges in Diagnosis

From a clinical standpoint, the challenge of diagnosing dyspnea is that it is very subjective. While spirometry tests (which measures lung capacity) and pulse oximetry (which measures oxygen levels in the blood) may show that two people have the same level of breathing impairment, one may feel completely winded after activity while the other may be just fine.

Ultimately, a person's perception of dyspnea is important as it helps ensure the person is neither undertreated nor overtreated and that the prescribed therapy, when needed, will improve the person's quality of life rather than take from it.  

To this end, pulmonologists will use a tool called the modified Medical Research Council (mMRC) dyspnea scale to establish how much an individual's shortness of breath causes real-world disability.

How the Assessment Is Performed

The process of measuring dyspnea is similar to tests used to measure pain perception in persons with chronic pain. Rather than defining dyspnea in terms of lung capacity, the mMRC scale will rate the sensation of dyspnea as the person perceives it.

The severity of dyspnea is rated on a scale of 0 to 4, the value of which will direct both the diagnosis and treatment plan.

Role of the MMRC Dyspnea Scale

The mMRC dyspnea scale has proven valuable in the field of pulmonology as it affords doctors and researchers the mean to:

• Assess the effectiveness of treatment on an individual basis
• Compare the effectiveness of a treatment within a population
• Predict survival times and rates

From a clinical viewpoint, the mMRC scale correlates fairly well to such objective measures as pulmonary function tests and walk tests . Moreover, the values tend to be stable over time, meaning that they are far less prone to subjective variability that one might assume.  

Using the BODE Index to Predict Survival

The mMRC dyspnea scale is used to calculate the BODE index , a tool which helps estimate the survival times of people living with COPD.

The BODE Index is comprised of a person's body mass index ("B"), airway obstruction ("O"), dyspnea ("D"), and exercise tolerance ("E"). Each of these components is graded on a scale of either 0 to 1 or 0 to 3, the numbers of which are then tabulated for a final value.

The final value—ranging from as low as 0 to as high as 10—provides doctors a percentage of how likely a person is to survive for four years. The final BODE tabulation is described as follows:

• 0 to 2 points: 80 percent likelihood of survival
• 3 to 4 points: 67 percent likelihood of survival
• 5 of 6 points: 57 percent likelihood of survival
• 7 to 10 points: 18 percent likelihood of survival

The BODE values, whether large or small, are not set in stone. Changes to lifestyle and improved treatment adherence can improve long-term outcomes, sometimes dramatically. These include things like quitting smoking , improving your diet  and engaging in appropriate exercise to improve your respiratory capacity.

In the end, the numbers are simply a snapshot of current health, not a prediction of your mortality. Ultimately, the lifestyle choices you make can play a significant role in determining whether the odds are against you or in your favor.

Janssens T, De peuter S, Stans L, et al. Dyspnea perception in COPD: association between anxiety, dyspnea-related fear, and dyspnea in a pulmonary rehabilitation program . Chest. 2011;140(3):618-625. doi:10.1378/chest.10-3257

Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study . BMC Pulm Med . 2010;10:32. doi:10.1186/1471-2466-10-32

Esteban C, Quintana JM, Moraza J, et al. BODE-Index vs HADO-score in chronic obstructive pulmonary disease: Which one to use in general practice? . BMC Med . 2010;8:28. doi:10.1186/1741-7015-8-28

Chhabra, S., Gupta, A., and Khuma, M. " Evaluation of Three Scales of Dyspnea in Chronic Obstructive Pulmonary Disease. " Annals of Thoracic Medicine. 2009; 4(3):128-32. DOI: 10.4103/1817-1737.53351 .

Perez, T.; Burgel, P.; Paillasseur, J.; et al. " Modified Medical Research Council scale vs Baseline Dyspnea Index to Evaluate Dyspnea in Chronic Obstructive Pulmonary Disease. " International Journal of Chronic Obstructive Pulmonary Disease . 2015; 10:1663-72. DOI: 10.2147/COPD.S82408 .

By Deborah Leader, RN  Deborah Leader RN, PHN, is a registered nurse and medical writer who focuses on COPD.

• Research article
• Open access
• Published: 01 October 2012

The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study

• Claire Launois 1 ,
• Coralie Barbe 2 ,
• Eric Bertin 3 ,
• Julie Nardi 1 ,
• Jeanne-Marie Perotin 1 ,
• Sandra Dury 1 ,
• François Lebargy 1 &
• Gaëtan Deslee 1  

BMC Pulmonary Medicine volume  12 , Article number:  61 ( 2012 ) Cite this article

61k Accesses

79 Citations

2 Altmetric

Metrics details

Dyspnea is very frequent in obese subjects. However, its assessment is complex in clinical practice. The modified Medical Research Council scale (mMRC scale) is largely used in the assessment of dyspnea in chronic respiratory diseases, but has not been validated in obesity. The objectives of this study were to evaluate the use of the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute walk test (6MWT), lung function and biological parameters.

Forty-five obese subjects (17 M/28 F, BMI: 43 ± 9 kg/m 2 ) were included in this pilot study. Dyspnea in daily living was evaluated by the mMRC scale and exertional dyspnea was evaluated by the Borg scale after 6MWT. Pulmonary function tests included spirometry, plethysmography, diffusing capacity of carbon monoxide and arterial blood gases. Fasting blood glucose, total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide, C-reactive protein and hemoglobin levels were analyzed.

Eighty-four percent of patients had a mMRC ≥ 1 and 40% a mMRC ≥ 2. Compared to subjects with no dyspnea (mMRC = 0), a mMRC ≥ 1 was associated with a higher BMI (44 ± 9 vs 36 ± 5 kg/m 2 , p = 0.01), and a lower expiratory reserve volume (ERV) (50 ± 31 vs 91 ± 32%, p = 0.004), forced expiratory volume in one second (FEV 1 ) (86 ± 17 vs 101 ± 16%, p = 0.04) and distance covered in 6MWT (401 ± 107 vs 524 ± 72 m, p = 0.007). A mMRC ≥ 2 was associated with a higher Borg score after the 6MWT (4.7 ± 2.5 vs 6.5 ± 1.5, p < 0.05).

This study confirms that dyspnea is very frequent in obese subjects. The differences between the “dyspneic” and the “non dyspneic” groups assessed by the mMRC scale for BMI, ERV, FEV 1 and distance covered in 6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in obese subjects.

Peer Review reports

Obesity, defined as a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 , is a significant public health concern. According to the World Health Organization, worldwide obesity has more than doubled since 1980 and in 2008 there were about 1.5 billion overweight adults (25 ≤ BMI < 30 kg/m 2 ). Of these, over 200 million men and nearly 300 million women were obese [ 1 ].

Dyspnea is very frequent in obese subjects. In a large epidemiological study, 80% of obese patients reported dyspnea after climbing two flights of stairs [ 2 ]. In a series of patients with morbid obesity, Collet et al. found that patients with a BMI > 49 kg/m 2 had more severe dyspnea assessed with BDI (Baseline Dyspnea Index) than obese patients with a BMI ≤ 49 kg/m 2 [ 3 ]. The most frequent pulmonary function abnormalities associated with obesity [ 4 , 5 ] are a decrease in expiratory reserve volume (ERV) [ 6 – 8 ], functional residual capacity (FRC) [ 6 – 8 ], and an increase in oxygen consumption [ 9 ]. Although the mechanisms of dyspnea in obesity remain unclear, it is moderately correlated with lung function [ 3 , 10 – 16 ]. Of note, type 2 diabetes [ 17 ], insulin resistance [ 18 ] and metabolic syndrome [ 19 ] have been shown to be associated with reduced lung function in obesity. It must be pointed out that dyspnea is a complex subjective sensation which is difficult to assess in clinical practice. However, there is no specific scale to assess dyspnea in daily living in obesity. The modified Medical Research Council (mMRC) scale is the most commonly used validated scale to assess dyspnea in daily living in chronic respiratory diseases [ 20 – 22 ] but has never been assessed in the context of obesity without a coexisting pulmonary disease.

The objectives of this pilot study were to evaluate the use of the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute walk distance (6MWD), lung function and biological parameters.

Adult obese patients from the Department of Nutrition of the University Hospital of Reims (France) were consecutively referred for a systematic respiratory evaluation without specific reason and considered for inclusion in this study. Inclusion criteria were a BMI ≥ 30 kg/m 2 and an age > 18 year-old. Exclusion criteria were a known coexisting pulmonary or neuromuscular disease or an inability to perform a 6MWT or pulmonary function testing. The study was approved by the Institutional Review Board (IRB) of the University Hospital of Reims, and patient consent was waived.

Clinical characteristics and mMRC scale

Demographic data (age, sex), BMI, comorbidities, treatments and smoking status were systematically recorded. Dyspnea in daily living was evaluated by the mMRC scale which consists in five statements that describe almost the entire range of dyspnea from none (Grade 0) to almost complete incapacity (Grade 4) (Table 1 ).

• Six-minute walk test

The 6MWT was performed using the methodology specified by the American Thoracic Society (ATS-2002) [ 23 ]. The patients were instructed that the objective was to walk as far as possible during 6 minutes. The 6MWT was performed in a flat, long, covered corridor which was 30 meters long, meter-by-meter marked. Heart rate, oxygen saturation and modified Borg scale assessing subjectively the degree of dyspnea graded from 0 to 10, were collected at the beginning and at the end of the 6MWT. When the test was finished, the distance covered was calculated.

Pulmonary function tests

Pulmonary function tests (PFTs) included forced expiratory volume in one second (FEV 1 ), vital capacity (VC), forced vital capacity (FCV), FEV 1 /VC, functional residual capacity (FRC), expiratory reserve volume (ERV), residual volume (RV), total lung capacity (TLC) and carbon monoxide diffusing capacity of the lung (DLCO) (BodyBox 5500 Medisoft Sorinnes, Belgium). Results were expressed as the percentage of predicted values [ 24 ]. Arterial blood gases were measured in the morning in a sitting position.

Biological parameters

After 12 hours of fasting, blood glucose, glycated hemoglobin (HbAIc), total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide (NT-pro BNP), C-reactive protein (CRP) and hemoglobin levels were measured.

Statistical analysis

Quantitative variables are described as mean ± standard deviation (SD) and qualitative variables as number and percentage. Patients were separated in two groups according to their dyspnea: mMRC = 0 (no dyspnea in daily living) and mMRC ≥ 1 (dyspnea in daily living, ie at least short of breath when hurrying on level ground or walking up a slight hill).

Factors associated with mMRC scale were studied using Wilcoxon, Chi-square or Fisher exact tests. Factors associated with Borg scale were studied using Wilcoxon tests or Pearson’s correlation coefficients. A p value < 0.05 was considered statistically significant. All analysis were performed using SAS version 9.0 (SAS Inc, Cary, NC, USA).

Results and discussion

Demographic characteristics.

Fifty four consecutive patients with a BMI ≥ 30 kg/m 2 were considered for inclusion. Of these, 9 patients were excluded because of an inability to perform the 6MWT related to an osteoarticular disorder (n = 2) or because of a diagnosed respiratory disease (n = 7; 5 asthma, 1 hypersensitivity pneumonia and 1 right pleural effusion).

Results of 45 patients were considered in the final analysis. Demographic characteristics of the patients are presented in Table 2 . Mean BMI was 43 ± 9 kg/m 2 , with 55% of the patients presenting an extreme obesity (BMI ≥ 40 kg/m 2 , grade 3). Regarding smoking status, 56% of patients were never smokers and 11% were current smokers. The main comorbidities were hypertension (53%), dyslipidemia (40%) and diabetes (36%). Severe obstructive sleep apnea syndrome was present in 16 patients (43%).

Dyspnea assessment by the mMRC scale and 6MWT

Results of dyspnea assessment are presented in Table 3 . Dyspnea symptom assessed by the mMRC scale was very frequent in obese subjects with 84% (n = 38) of patients with a mMRC scale ≥ 1 and 40% (n = 18) of patients with a mMRC scale ≥ 2 (29% mMRC = 2, 9% mMRC = 3 and 2% mMRC = 4).

The mean distance covered in 6MWT was 420 ± 112 m. Sixteen percent of patients had a decrease > 4% of SpO2 during the 6MWT and one patient had a SpO2 < 90% at the end of the 6MWT (Table 4 ). The dyspnea sensation at rest was very slight (Borg = 1 ± 1.5) but severe after exertion (Borg = 5.4 ± 2.4). Fifty-three percent of patients exhibited a Borg scale ≥ 5 after the 6MWT which is considered as severe exertional dyspnea. No complication occurred during the 6MWT. Subjects with a mMRC score ≥ 2 had a higher Borg score after the 6MWT than subjects with a mMRC score < 2 (6.5 ± 1.5 vs 4.7 ± 2.5, p < 0.05).

Lung function tests

Results of spirometry, plethysmography and arterial blood gases are shown in Table 4 . Overall, the PFTs results remained in the normal range for most of the patients, except for ERV predicted values which were lower (ERV = 56 ± 34%). There were an obstructive ventilatory disorder defined by a FEV 1 /VC < 0.7 in 5 patients (11%) with 5 patients (13%) exhibiting a mMRC ≥ 1, a restrictive ventilatory disorder defined by a TLC < 80% in 5 patients (13%) with 5 patients (16%) exhibiting a mMRC ≥ 1, and a decrease in alveolar diffusion defined by DLCO < 70% in 10 patients (26%) with 9 patients (28%) exhibiting a mMRC ≥ 1. Arterial blood gases at rest were in the normal range with no hypoxemia < 70 mmHg and no significant hypercapnia > 45 mmHg.

Fifteen percent (n = 7) of patients presented anemia. All patients had a hemoglobin level ≥ 11 g/dL. Mean NT pro-BNP was 117 ± 285 pg/mL. Four patients (10%) had a pro-BNP > 300 pg/mL.Forty-five percent of patients had a fasting glucose level > 7 mmol/L, 51% a Hba1c > 6%, 29% a triglyceride level ≥ 1.7 mmol/L, 35% a total cholesterol level > 5.2 mmol/L and 31% a CRP level > 10 mg/L.

Relationships between the mMRC scale and clinical characteristics, PFTs and biological parameters

The comparisons between the mMRC scale and demographic, lung functional and biological parameters are shown in Table 5 . Subjects in the mMRC ≥ 1 group had a higher BMI (p = 0.01) (Figure 1 A), lower ERV (p < 0.005) (Figure 1 B), FEV 1 (p < 0.05), covered distance in 6MWT (p < 0.01) (Figure 1 C) and Hb level (p < 0.05) than subjects in the mMRC = 0 group. Of note, there was no association between the mMRC scale and age, sex, smoking history, arterial blood gases, metabolic parameters and the apnea/hypopnea index.

Differences in Body Mass Index (BMI) (A), Expiratory reserve volume (ERV) (B) and 6-minute walk distance (C) between non-dyspneic (modified Medical Research Council score = 0) and dyspneic (mMRC score ≥ 1) subjects. *p < 0.05, **p < 0.01. A Wilcoxon test was used.

The relationships between the Borg scale after 6MWT and demographic, lung functional and biological parameters were also analysed. The Borg score after 6MWT was correlated with a higher BMI (correlation coefficient = +0.44, p < 0.005) and a lower FEV 1 (correlation coefficient = -0.33, p < 0.05). No relationship was found between the Borg score after 6MWT and ERV or hemoglobin level. The Borg score after 6MWT was correlated with a higher fasting glucose (correlation coefficient = +0.46, p < 0.005) whereas this parameter was not associated with the mMRC scale (data not shown). We found no statistically different change in Borg scale ratings of dyspnea from rest to the end of the 6MWT between the two groups (p = 0.39).

In this study, 45 consecutive obese subjects were specifically assessed for dyspnea in daily living using the mMRC scale. Our study confirms the high prevalence of dyspnea in daily living in obese subjects [ 2 ] with 84% of patients exhibiting a mMRC scale ≥ 1 and 40% a mMRC scale ≥ 2. Interestingly, the presence of dyspnea in daily living (mMRC ≥ 1) was associated with a higher BMI and a lower ERV, FEV 1 , distance covered in 6MWT and hemoglobin level. Furthermore, a mMRC score ≥ 2 in obese subjects was associated with a higher Borg score after the 6MWT (data not shown).

The assessment of dyspnea in clinical practice is difficult. Regarding the mMRC scale, two versions of this scale have been used, one with 5 grades [ 20 ] as used in this study and an other with 6 grades [ 25 ] leading to some confusion. Other scales have been also used to assess dyspnea [ 26 ]. Collet at al. [ 3 ], Ofir et al. [ 11 ] and El-Gamal [ 27 ] et al provided some evidence to support the use of the BDI, Oxygen cost diaphragm (OCD) and Chronic Respiratory Disease Questionnaire (CRQ) to evaluate dyspnea in obesity. El-Gamal et al [ 27 ] demonstated the responsiveness of the CRQ in obesity as they did measurements before and after gastroplaty-induced weight loss within the same subjects. The Baseline Dyspnea Index (BDI) uses five grades (0 to 4) for 3 categories, functional impairment, magnitude of task and magnitude of effort with a total score from 0 to 12 [ 28 ]. The University of California San Diego Shortness of Breath Questionnaire comprises 24 items assessing dyspnea over the previous week [ 29 ]. It must be pointed out that these scores are much more time consuming than the mMRC scale and are difficult to apply in clinical practice.

To our knowledge, the mMRC scale has not been investigated in the assessment of dyspnea in daily living in obese subjects without a coexisting pulmonary disease. The mMRC scale is an unidimensional scale related to activities of daily living which is widely used and well correlated with quality of life in chronic respiratory diseases [ 20 ] such as chronic obstructive pulmonary disease (COPD) [ 21 ] or idiopathic pulmonary fibrosis [ 22 ]. The mMRC scale is easy-to-use and not time consuming, based on five statements describing almost the entire range of dyspnea in daily living. Our study provides evidence for the use of the mMRC scale in the assessment of dyspnea in daily living in obese subjects. Firstly, as expected, our results demonstrate an association between the mMRC scale and the BMI in the comparison between “dyspneic” and “non dyspneic” groups. Secondly, in our between-group comparisons, the mMRC scale was associated with pulmonary functional parameters (lower ERV, FEV 1 and distance walked in 6MWT) which might be involved in dyspnea in obesity. The reduction in ERV is the most frequent functional respiratory abnormality reported in obesity [ 6 – 8 ]. This decrease is correlated exponentially with BMI and is mainly due to the effect of the abdominal contents on diaphragm position [ 30 ]. While the FEV 1 might be slightly reduced in patients with severe obesity, the FEV 1 /VC is preserved as seen in our study [ 31 ]. The determination of the walking distance and the Borg scale using the 6MWT is known to be a simple method to assess the limitations of exercise capacity in chronic respiratory diseases [ 23 ]. Two studies have shown a good reproducibility of this test [ 32 , 33 ] but did not investigate the relationships between the 6MWD and dyspnea in daily living. Our study confirms the feasibility of the 6MWD in clinical practice in obesity and demonstrates an association between covered distance in 6MWT and the presence or the absence of dyspnea in daily living assessed by the mMRC scale. It must be pointed out that the 6MWT is not a standardized exercise stimulus. Exercise testing using cycloergometer or the shuttle walking test could be of interest to determine the relationships between the mMRC scale and a standardize exercise stimulus. In our between-group comparisons, BMI and FEV 1 were associated with the mMRC scale and correlated with the Borg scale after 6MWT. Surprisingly, the ERV was associated with the mMRC scale but not with the Borg scale. Moreover, the fasting glucose was correlated with the Borg scale after 6MWT but not associated with the mMRC scale. Whether these differences are due to a differential involvement of these parameters in dyspnea in daily living and at exercise, or simply related to a low sample size remains to be evaluated.

As type 2 diabetes, insulin resistance, metabolic syndrome [ 17 – 19 ], anemia and cardiac insufficiency have been shown to be associated with lung function and/or dyspnea, we also investigated the relationships between dyspnea in daily living and biological parameters. A mMRC scale ≥ 1 was associated with a lower hemoglobin level. However, all patients had a hemoglobin level > 11 g/dL and the clinical significance of the association between dyspnea in daily living and a mildly lower hemoglobin level has to be interpreted cautiously and remains to be evaluated. Of note, we did not find any associations between the mMRC scale and triglyceride, total cholesterol, fasting glucose, HbA1C, CRP or NT pro-BNP.

The strength of this study includes the assessment of the relationships between the mMRC scale and multidimensional parameters including exertional dyspnea assessed by the Borg score after 6MWT, PFTs and biological parameters. The limitations of this pilot study are as follows. Firstly, the number of patients included is relatively low. This study was monocentric and did not include control groups of overweight and normal weight subjects. Due to the limited number of patients, our study did not allow the analysis sex differences in the perception of dyspnea. Secondly, we did not investigate the relationships between the mMRC scale and other dyspnea scales like the BDI which has been evaluated in obese subjects and demonstrated some correlations with lung function [ 3 ]. Thirdly, it would have been interesting to assess the relationships between the mMRC scale and cardio-vascular, neuromuscular and psycho-emotional parameters which might be involved in dyspnea. Assessing the relationships between health related quality of life and dyspnea would also be useful. Finally, fat distribution (eg Waist circumferences or waist/hip ratios) has not been specifically assessed in our study but might be assessed at contributing factor to dyspnea. Despite these limitations, this pilot study suggests that the mMRC scale might be of value in the assessment of dyspnea in obesity and might be used as a dyspnea scale in further larger multicentric studies. It remains to be seen whether it is sensitive to changes with intervention.

Conclusions

This pilot study investigated the potential use of the mMRC scale in obesity. The differences observed between the “dyspneic” and the “non dyspneic” groups as defined by the mMRC scale with respect to BMI, ERV, FEV 1 and distance covered in 6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in obese subjects.

Abbreviations

Body Mass Index

• Modified Medical Research Council scale

Expiratory volume in one second

Vital capacity

Forced vital capacity

Functional residual capacity

Expiratory reserve volume

Residual volume

Total lung capacity

Carbon monoxide diffusing capacity of the lung

Glycated hemoglobin

N-terminal pro brain natriuretic peptide

Serum C reactive protein.

WHO: Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ ,

Sjöström L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karlsson J, Lapidus L: Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord. 1992, 16: 465-479.

PubMed   Google Scholar  

Collet F, Mallart A, Bervar JF, Bautin N, Matran R, Pattou F, Romon M, Perez T: Physiologic correlates of dyspnea in patients with morbid obesity. Int J Obes (Lond). 2007, 31: 700-706.

CAS   Google Scholar  

Salome CM, King GG, Berend N: Physiology of obesity and effects on lung function. J Appl Physiol. 2010, 108: 206-211. 10.1152/japplphysiol.00694.2009.

Article   PubMed   Google Scholar  

Gibson GJ: Obesity, respiratory function and breathlessness. Thorax. 2000, 55 (Suppl 1): S41-S44.

Article   PubMed   PubMed Central   Google Scholar  

Ray CS, Sue DY, Bray G, Hansen JE, Wasserman K: Effects of obesity on respiratory function. Am Rev Respir Dis. 1983, 128: 501-506.

Article   CAS   PubMed   Google Scholar  

Jones RL, Nzekwu M-MU: The effects of body mass index on lung volumes. Chest. 2006, 130: 827-833. 10.1378/chest.130.3.827.

Biring MS, Lewis MI, Liu JT, Mohsenifar Z: Pulmonary physiologic changes of morbid obesity. Am J Med Sci. 1999, 318: 293-297. 10.1097/00000441-199911000-00002.

Babb TG, Ranasinghe KG, Comeau LA, Semon TL, Schwartz B: Dyspnea on exertion in obese women: association with an increased oxygen cost of breathing. Am J Respir Crit Care Med. 2008, 178: 116-123. 10.1164/rccm.200706-875OC.

Sahebjami H: Dyspnea in obese healthy men. Chest. 1998, 114: 1373-1377. 10.1378/chest.114.5.1373.

Ofir D, Laveneziana P, Webb KA, O’Donnell DE: Ventilatory and perceptual responses to cycle exercise in obese women. J Appl Physiol. 2007, 102: 2217-2226. 10.1152/japplphysiol.00898.2006.

Romagnoli I, Laveneziana P, Clini EM, Palange P, Valli G, de Blasio F, Gigliotti F, Scano G: Role of hyperinflation vs. deflation on dyspnoea in severely to extremely obese subjects. Acta Physiol (Oxf). 2008, 193: 393-402. 10.1111/j.1748-1716.2008.01852.x.

Article   CAS   Google Scholar  

Jensen D, Webb KA, Wolfe LA, O’Donnell DE: Effects of human pregnancy and advancing gestation on respiratory discomfort during exercise. Respir Physiol Neurobiol. 2007, 156: 85-93. 10.1016/j.resp.2006.08.004.

Scano G, Stendardi L, Bruni GI: The respiratory muscles in eucapnic obesity: their role in dyspnea. Respir Med. 2009, 103: 1276-1285. 10.1016/j.rmed.2009.03.023.

Ora J, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O’Donnell DE: Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med. 2009, 180: 964-971.

Sava F, Laviolette L, Bernard S, Breton M-J, Bourbeau J, Maltais F: The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med. 2010, 10: 55-10.1186/1471-2466-10-55.

Lecube A, Sampol G, Muñoz X, Hernández C, Mesa J, Simó R: Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study. Diabetologia. 2010, 53: 1210-1216. 10.1007/s00125-010-1700-5.

Lecube A, Sampol G, Muñoz X, Lloberes P, Hernández C, Simó R: Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study. Diabetes Metab Res Rev. 2010, 26: 639-645. 10.1002/dmrr.1131.

Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, Guize L, Zureik M: Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009, 179: 509-516. 10.1164/rccm.200807-1195OC.

Mahler DA, Wells CK: Evaluation of clinical methods for rating dyspnea. Chest. 1988, 93: 580-586. 10.1378/chest.93.3.580.

Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Analysis of Clinical Methods Used to Evaluate Dyspnea in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 1998, 158: 1185-1189.

Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S: A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010, 36: 1067-1072. 10.1183/09031936.00152609.

ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166: 111-117.

Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 1-100.

Eltayara L, Becklake MR, Volta CA, Milic-Emili J: Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996, 154: 1726-1734.

Gerlach Y, Williams MT, Coates AM: Weighing up the evidence-a systematic review of measures used for the sensation of breathlessness in obesity. Int J Obes. 2012

Google Scholar  

El-Gamal H, Khayat A, Shikora S, Unterborn JN: Relationship of dyspnea to respiratory drive and pulmonary function tests in obese patients before and after weight loss. Chest. 2005, 128: 3870-3874. 10.1378/chest.128.6.3870.

Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984, 85: 751-758. 10.1378/chest.85.6.751.

Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM: Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998, 113: 619-624. 10.1378/chest.113.3.619.

Parameswaran K, Todd DC, Soth M: Altered respiratory physiology in obesity. Can Respir J. 2006, 13: 203-210.

Sin DD, Jones RL, Man SFP: Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med. 2002, 162: 1477-1481. 10.1001/archinte.162.13.1477.

Beriault K, Carpentier AC, Gagnon C, Ménard J, Baillargeon J-P, Ardilouze J-L, Langlois M-F: Reproducibility of the 6-minute walk test in obese adults. Int J Sports Med. 2009, 30: 725-727. 10.1055/s-0029-1231043.

Larsson UE, Reynisdottir S: The six-minute walk test in outpatients with obesity: reproducibility and known group validity. Physiother Res Int. 2008, 13: 84-93. 10.1002/pri.398.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2466/12/61/prepub

Download references

Acknowledgements

We thank the personnel of the Department of Nutrition and Pulmonary Medicine of the University Hospital of Reims for the selection and clinical/functional assessment of the patients.

Author information

Authors and affiliations.

Service des Maladies Respiratoires, INSERM UMRS 903, Hôpital Maison Blanche, CHU de Reims, 45 rue Cognacq Jay 51092, Reims, Cedex, France

Claire Launois, Julie Nardi, Jeanne-Marie Perotin, Sandra Dury, François Lebargy & Gaëtan Deslee

Unité d'Aide Méthodologique, Pôle Recherche et Innovations, Hôpital Robert Debré, CHU de Reims, Reims, France

Coralie Barbe

Service d’Endocrinologie-Diabétologie-Nutrition, Hôpital Robert Debré, CHU de Reims, Reims, France

Eric Bertin

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Claire Launois .

Additional information

Competing interests.

None of the authors of the present manuscript have a commercial or other association that might pose a conflict of interest.

Authors’ contributions

CL, CB, EB, JN, JMP, SD, FL and GD conceived the study. CL acquired data. CB performed the statistical analysis. CL and GD drafted the manuscript. All authors read and approved the manuscript prior to submission.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions.

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article.

Launois, C., Barbe, C., Bertin, E. et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study. BMC Pulm Med 12 , 61 (2012). https://doi.org/10.1186/1471-2466-12-61

Download citation

Received : 06 April 2012

Accepted : 22 September 2012

Published : 01 October 2012

DOI : https://doi.org/10.1186/1471-2466-12-61

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Lung function

BMC Pulmonary Medicine

ISSN: 1471-2466

• Submission enquiries: [email protected]
• General enquiries: [email protected]

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• BMC Pulm Med

The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study

Claire launois.

1 Service des Maladies Respiratoires, INSERM UMRS 903, Hôpital Maison Blanche, CHU de Reims, 45 rue Cognacq Jay 51092, Reims, Cedex, France

Coralie Barbe

2 Unité d'Aide Méthodologique, Pôle Recherche et Innovations, Hôpital Robert Debré, CHU de Reims, Reims, France

Eric Bertin

3 Service d’Endocrinologie-Diabétologie-Nutrition, Hôpital Robert Debré, CHU de Reims, Reims, France

Julie Nardi

Jeanne-marie perotin, sandra dury, françois lebargy, gaëtan deslee.

Dyspnea is very frequent in obese subjects. However, its assessment is complex in clinical practice. The modified Medical Research Council scale (mMRC scale) is largely used in the assessment of dyspnea in chronic respiratory diseases, but has not been validated in obesity. The objectives of this study were to evaluate the use of the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute walk test (6MWT), lung function and biological parameters.

Forty-five obese subjects (17 M/28 F, BMI: 43 ± 9 kg/m 2 ) were included in this pilot study. Dyspnea in daily living was evaluated by the mMRC scale and exertional dyspnea was evaluated by the Borg scale after 6MWT. Pulmonary function tests included spirometry, plethysmography, diffusing capacity of carbon monoxide and arterial blood gases. Fasting blood glucose, total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide, C-reactive protein and hemoglobin levels were analyzed.

Eighty-four percent of patients had a mMRC ≥ 1 and 40% a mMRC ≥ 2. Compared to subjects with no dyspnea (mMRC = 0), a mMRC ≥ 1 was associated with a higher BMI (44 ± 9 vs 36 ± 5 kg/m 2 , p = 0.01), and a lower expiratory reserve volume (ERV) (50 ± 31 vs 91 ± 32%, p = 0.004), forced expiratory volume in one second (FEV 1 ) (86 ± 17 vs 101 ± 16%, p = 0.04) and distance covered in 6MWT (401 ± 107 vs 524 ± 72 m, p = 0.007). A mMRC ≥ 2 was associated with a higher Borg score after the 6MWT (4.7 ± 2.5 vs 6.5 ± 1.5, p < 0.05).

This study confirms that dyspnea is very frequent in obese subjects. The differences between the “dyspneic” and the “non dyspneic” groups assessed by the mMRC scale for BMI, ERV, FEV 1 and distance covered in 6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in obese subjects.

Obesity, defined as a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 , is a significant public health concern. According to the World Health Organization, worldwide obesity has more than doubled since 1980 and in 2008 there were about 1.5 billion overweight adults (25 ≤ BMI < 30 kg/m 2 ). Of these, over 200 million men and nearly 300 million women were obese [ 1 ].

Dyspnea is very frequent in obese subjects. In a large epidemiological study, 80% of obese patients reported dyspnea after climbing two flights of stairs [ 2 ]. In a series of patients with morbid obesity, Collet et al. found that patients with a BMI > 49 kg/m 2 had more severe dyspnea assessed with BDI (Baseline Dyspnea Index) than obese patients with a BMI ≤ 49 kg/m 2 [ 3 ]. The most frequent pulmonary function abnormalities associated with obesity [ 4 , 5 ] are a decrease in expiratory reserve volume (ERV) [ 6 - 8 ], functional residual capacity (FRC) [ 6 - 8 ], and an increase in oxygen consumption [ 9 ]. Although the mechanisms of dyspnea in obesity remain unclear, it is moderately correlated with lung function [ 3 , 10 - 16 ]. Of note, type 2 diabetes [ 17 ], insulin resistance [ 18 ] and metabolic syndrome [ 19 ] have been shown to be associated with reduced lung function in obesity. It must be pointed out that dyspnea is a complex subjective sensation which is difficult to assess in clinical practice. However, there is no specific scale to assess dyspnea in daily living in obesity. The modified Medical Research Council (mMRC) scale is the most commonly used validated scale to assess dyspnea in daily living in chronic respiratory diseases [ 20 - 22 ] but has never been assessed in the context of obesity without a coexisting pulmonary disease.

The objectives of this pilot study were to evaluate the use of the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute walk distance (6MWD), lung function and biological parameters.

Adult obese patients from the Department of Nutrition of the University Hospital of Reims (France) were consecutively referred for a systematic respiratory evaluation without specific reason and considered for inclusion in this study. Inclusion criteria were a BMI ≥ 30 kg/m 2 and an age > 18 year-old. Exclusion criteria were a known coexisting pulmonary or neuromuscular disease or an inability to perform a 6MWT or pulmonary function testing. The study was approved by the Institutional Review Board (IRB) of the University Hospital of Reims, and patient consent was waived.

Clinical characteristics and mMRC scale

Demographic data (age, sex), BMI, comorbidities, treatments and smoking status were systematically recorded. Dyspnea in daily living was evaluated by the mMRC scale which consists in five statements that describe almost the entire range of dyspnea from none (Grade 0) to almost complete incapacity (Grade 4) (Table ​ (Table1 1 ).

The modified Medical Research Council (mMRC) scale

Six-minute walk test

The 6MWT was performed using the methodology specified by the American Thoracic Society (ATS-2002) [ 23 ]. The patients were instructed that the objective was to walk as far as possible during 6 minutes. The 6MWT was performed in a flat, long, covered corridor which was 30 meters long, meter-by-meter marked. Heart rate, oxygen saturation and modified Borg scale assessing subjectively the degree of dyspnea graded from 0 to 10, were collected at the beginning and at the end of the 6MWT. When the test was finished, the distance covered was calculated.

Pulmonary function tests

Pulmonary function tests (PFTs) included forced expiratory volume in one second (FEV 1 ), vital capacity (VC), forced vital capacity (FCV), FEV 1 /VC, functional residual capacity (FRC), expiratory reserve volume (ERV), residual volume (RV), total lung capacity (TLC) and carbon monoxide diffusing capacity of the lung (DLCO) (BodyBox 5500 Medisoft Sorinnes, Belgium). Results were expressed as the percentage of predicted values [ 24 ]. Arterial blood gases were measured in the morning in a sitting position.

Biological parameters

After 12 hours of fasting, blood glucose, glycated hemoglobin (HbAIc), total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide (NT-pro BNP), C-reactive protein (CRP) and hemoglobin levels were measured.

Statistical analysis

Quantitative variables are described as mean ± standard deviation (SD) and qualitative variables as number and percentage. Patients were separated in two groups according to their dyspnea: mMRC = 0 (no dyspnea in daily living) and mMRC ≥ 1 (dyspnea in daily living, ie at least short of breath when hurrying on level ground or walking up a slight hill).

Factors associated with mMRC scale were studied using Wilcoxon, Chi-square or Fisher exact tests. Factors associated with Borg scale were studied using Wilcoxon tests or Pearson’s correlation coefficients. A p value < 0.05 was considered statistically significant. All analysis were performed using SAS version 9.0 (SAS Inc, Cary, NC, USA).

Results and discussion

Demographic characteristics.

Fifty four consecutive patients with a BMI ≥ 30 kg/m 2 were considered for inclusion. Of these, 9 patients were excluded because of an inability to perform the 6MWT related to an osteoarticular disorder (n = 2) or because of a diagnosed respiratory disease (n = 7; 5 asthma, 1 hypersensitivity pneumonia and 1 right pleural effusion).

Results of 45 patients were considered in the final analysis. Demographic characteristics of the patients are presented in Table ​ Table2. 2 . Mean BMI was 43 ± 9 kg/m 2 , with 55% of the patients presenting an extreme obesity (BMI ≥ 40 kg/m 2 , grade 3). Regarding smoking status, 56% of patients were never smokers and 11% were current smokers. The main comorbidities were hypertension (53%), dyslipidemia (40%) and diabetes (36%). Severe obstructive sleep apnea syndrome was present in 16 patients (43%).

Clinical characteristics of the 45 adult obese patients

Data are expressed as mean ± SD or number (%).

Dyspnea assessment by the mMRC scale and 6MWT

Results of dyspnea assessment are presented in Table ​ Table3. 3 . Dyspnea symptom assessed by the mMRC scale was very frequent in obese subjects with 84% (n = 38) of patients with a mMRC scale ≥ 1 and 40% (n = 18) of patients with a mMRC scale ≥ 2 (29% mMRC = 2, 9% mMRC = 3 and 2% mMRC = 4).

Dyspnea assessment of the 45 adult obese patients

mMRC: modified Medical Research Council, 6MWT: six-minute walk test.

The mean distance covered in 6MWT was 420 ± 112 m. Sixteen percent of patients had a decrease > 4% of SpO2 during the 6MWT and one patient had a SpO2 < 90% at the end of the 6MWT (Table ​ (Table4). 4 ). The dyspnea sensation at rest was very slight (Borg = 1 ± 1.5) but severe after exertion (Borg = 5.4 ± 2.4). Fifty-three percent of patients exhibited a Borg scale ≥ 5 after the 6MWT which is considered as severe exertional dyspnea. No complication occurred during the 6MWT. Subjects with a mMRC score ≥ 2 had a higher Borg score after the 6MWT than subjects with a mMRC score < 2 (6.5 ± 1.5 vs 4.7 ± 2.5, p < 0.05).

Functional characteristics of the 45 adult obese patients

FEV 1 : expiratory volume in one second, VC: vital capacity, FRC: functional residual capacity, ERV: expiratory reserve volume, TLC: total lung capacity, DLCO: carbon monoxide diffusing capacity of the lung, pred: predicted value, 6MWT: six-minute walk test.

Lung function tests

Results of spirometry, plethysmography and arterial blood gases are shown in Table ​ Table4. 4 . Overall, the PFTs results remained in the normal range for most of the patients, except for ERV predicted values which were lower (ERV = 56 ± 34%). There were an obstructive ventilatory disorder defined by a FEV 1 /VC < 0.7 in 5 patients (11%) with 5 patients (13%) exhibiting a mMRC ≥ 1, a restrictive ventilatory disorder defined by a TLC < 80% in 5 patients (13%) with 5 patients (16%) exhibiting a mMRC ≥ 1, and a decrease in alveolar diffusion defined by DLCO < 70% in 10 patients (26%) with 9 patients (28%) exhibiting a mMRC ≥ 1. Arterial blood gases at rest were in the normal range with no hypoxemia < 70 mmHg and no significant hypercapnia > 45 mmHg.

Fifteen percent (n = 7) of patients presented anemia. All patients had a hemoglobin level ≥ 11 g/dL. Mean NT pro-BNP was 117 ± 285 pg/mL. Four patients (10%) had a pro-BNP > 300 pg/mL.Forty-five percent of patients had a fasting glucose level > 7 mmol/L, 51% a Hba1c > 6%, 29% a triglyceride level ≥ 1.7 mmol/L, 35% a total cholesterol level > 5.2 mmol/L and 31% a CRP level > 10 mg/L.

Relationships between the mMRC scale and clinical characteristics, PFTs and biological parameters

The comparisons between the mMRC scale and demographic, lung functional and biological parameters are shown in Table ​ Table5. 5 . Subjects in the mMRC ≥ 1 group had a higher BMI (p = 0.01) (Figure ​ (Figure1A), 1 A), lower ERV (p < 0.005) (Figure ​ (Figure1B), 1 B), FEV 1 (p < 0.05), covered distance in 6MWT (p < 0.01) (Figure ​ (Figure1C) 1 C) and Hb level (p < 0.05) than subjects in the mMRC = 0 group. Of note, there was no association between the mMRC scale and age, sex, smoking history, arterial blood gases, metabolic parameters and the apnea/hypopnea index.

Comparisons of patients with mMRC = 0 and patients with mMRC ≥ 1 concerning clinical characteristics, lung function and biological parameters

Data are expressed as number (%) or mean ± SD; *p value < 0.05, **p value < 0.01.

FEV 1 : expiratory volume in one second, pred: predicted value, VC: vital capacity, FRC: functional residual capacity, ERV: expiratory reserve volume, TLC: total lung capacity, DLCO: carbon monoxide diffusing capacity of the lung, NT pro-BNP: N-terminal pro brain natriuretic peptide, CRP: serum C reactive protein, HbA1c: glycated hemoglobin.

Normal biological parameters values were based on the normal values for our laboratory: fasting glucose: 3.3 to 6.1 mmol/L; HbA1c: 4 to 6%; total cholesterol: 3 to 5.2 mmol/L; triglycerides: 0.3 to 1.7 mmol/L; NT-pro BNP < 300 pg/mL; CRP < 10 mg/L. Anemia was defined as hemoglobin level < 13 g/dL in men and 12 g/dL in women.

Differences in Body Mass Index (BMI) (A), Expiratory reserve volume (ERV) (B) and 6-minute walk distance (C) between non-dyspneic (modified Medical Research Council score = 0) and dyspneic (mMRC score ≥ 1) subjects. *p < 0.05, **p < 0.01. A Wilcoxon test was used.

The relationships between the Borg scale after 6MWT and demographic, lung functional and biological parameters were also analysed. The Borg score after 6MWT was correlated with a higher BMI (correlation coefficient = +0.44, p < 0.005) and a lower FEV 1 (correlation coefficient = -0.33, p < 0.05). No relationship was found between the Borg score after 6MWT and ERV or hemoglobin level. The Borg score after 6MWT was correlated with a higher fasting glucose (correlation coefficient = +0.46, p < 0.005) whereas this parameter was not associated with the mMRC scale (data not shown). We found no statistically different change in Borg scale ratings of dyspnea from rest to the end of the 6MWT between the two groups (p = 0.39).

In this study, 45 consecutive obese subjects were specifically assessed for dyspnea in daily living using the mMRC scale. Our study confirms the high prevalence of dyspnea in daily living in obese subjects [ 2 ] with 84% of patients exhibiting a mMRC scale ≥ 1 and 40% a mMRC scale ≥ 2. Interestingly, the presence of dyspnea in daily living (mMRC ≥ 1) was associated with a higher BMI and a lower ERV, FEV 1 , distance covered in 6MWT and hemoglobin level. Furthermore, a mMRC score ≥ 2 in obese subjects was associated with a higher Borg score after the 6MWT (data not shown).

The assessment of dyspnea in clinical practice is difficult. Regarding the mMRC scale, two versions of this scale have been used, one with 5 grades [ 20 ] as used in this study and an other with 6 grades [ 25 ] leading to some confusion. Other scales have been also used to assess dyspnea [ 26 ]. Collet at al. [ 3 ], Ofir et al. [ 11 ] and El-Gamal [ 27 ] et al provided some evidence to support the use of the BDI, Oxygen cost diaphragm (OCD) and Chronic Respiratory Disease Questionnaire (CRQ) to evaluate dyspnea in obesity. El-Gamal et al [ 27 ] demonstated the responsiveness of the CRQ in obesity as they did measurements before and after gastroplaty-induced weight loss within the same subjects. The Baseline Dyspnea Index (BDI) uses five grades (0 to 4) for 3 categories, functional impairment, magnitude of task and magnitude of effort with a total score from 0 to 12 [ 28 ]. The University of California San Diego Shortness of Breath Questionnaire comprises 24 items assessing dyspnea over the previous week [ 29 ]. It must be pointed out that these scores are much more time consuming than the mMRC scale and are difficult to apply in clinical practice.

To our knowledge, the mMRC scale has not been investigated in the assessment of dyspnea in daily living in obese subjects without a coexisting pulmonary disease. The mMRC scale is an unidimensional scale related to activities of daily living which is widely used and well correlated with quality of life in chronic respiratory diseases [ 20 ] such as chronic obstructive pulmonary disease (COPD) [ 21 ] or idiopathic pulmonary fibrosis [ 22 ]. The mMRC scale is easy-to-use and not time consuming, based on five statements describing almost the entire range of dyspnea in daily living. Our study provides evidence for the use of the mMRC scale in the assessment of dyspnea in daily living in obese subjects. Firstly, as expected, our results demonstrate an association between the mMRC scale and the BMI in the comparison between “dyspneic” and “non dyspneic” groups. Secondly, in our between-group comparisons, the mMRC scale was associated with pulmonary functional parameters (lower ERV, FEV 1 and distance walked in 6MWT) which might be involved in dyspnea in obesity. The reduction in ERV is the most frequent functional respiratory abnormality reported in obesity [ 6 - 8 ]. This decrease is correlated exponentially with BMI and is mainly due to the effect of the abdominal contents on diaphragm position [ 30 ]. While the FEV 1 might be slightly reduced in patients with severe obesity, the FEV 1 /VC is preserved as seen in our study [ 31 ]. The determination of the walking distance and the Borg scale using the 6MWT is known to be a simple method to assess the limitations of exercise capacity in chronic respiratory diseases [ 23 ]. Two studies have shown a good reproducibility of this test [ 32 , 33 ] but did not investigate the relationships between the 6MWD and dyspnea in daily living. Our study confirms the feasibility of the 6MWD in clinical practice in obesity and demonstrates an association between covered distance in 6MWT and the presence or the absence of dyspnea in daily living assessed by the mMRC scale. It must be pointed out that the 6MWT is not a standardized exercise stimulus. Exercise testing using cycloergometer or the shuttle walking test could be of interest to determine the relationships between the mMRC scale and a standardize exercise stimulus. In our between-group comparisons, BMI and FEV 1 were associated with the mMRC scale and correlated with the Borg scale after 6MWT. Surprisingly, the ERV was associated with the mMRC scale but not with the Borg scale. Moreover, the fasting glucose was correlated with the Borg scale after 6MWT but not associated with the mMRC scale. Whether these differences are due to a differential involvement of these parameters in dyspnea in daily living and at exercise, or simply related to a low sample size remains to be evaluated.

As type 2 diabetes, insulin resistance, metabolic syndrome [ 17 - 19 ], anemia and cardiac insufficiency have been shown to be associated with lung function and/or dyspnea, we also investigated the relationships between dyspnea in daily living and biological parameters. A mMRC scale ≥ 1 was associated with a lower hemoglobin level. However, all patients had a hemoglobin level > 11 g/dL and the clinical significance of the association between dyspnea in daily living and a mildly lower hemoglobin level has to be interpreted cautiously and remains to be evaluated. Of note, we did not find any associations between the mMRC scale and triglyceride, total cholesterol, fasting glucose, HbA1C, CRP or NT pro-BNP.

The strength of this study includes the assessment of the relationships between the mMRC scale and multidimensional parameters including exertional dyspnea assessed by the Borg score after 6MWT, PFTs and biological parameters. The limitations of this pilot study are as follows. Firstly, the number of patients included is relatively low. This study was monocentric and did not include control groups of overweight and normal weight subjects. Due to the limited number of patients, our study did not allow the analysis sex differences in the perception of dyspnea. Secondly, we did not investigate the relationships between the mMRC scale and other dyspnea scales like the BDI which has been evaluated in obese subjects and demonstrated some correlations with lung function [ 3 ]. Thirdly, it would have been interesting to assess the relationships between the mMRC scale and cardio-vascular, neuromuscular and psycho-emotional parameters which might be involved in dyspnea. Assessing the relationships between health related quality of life and dyspnea would also be useful. Finally, fat distribution (eg Waist circumferences or waist/hip ratios) has not been specifically assessed in our study but might be assessed at contributing factor to dyspnea. Despite these limitations, this pilot study suggests that the mMRC scale might be of value in the assessment of dyspnea in obesity and might be used as a dyspnea scale in further larger multicentric studies. It remains to be seen whether it is sensitive to changes with intervention.

Conclusions

This pilot study investigated the potential use of the mMRC scale in obesity. The differences observed between the “dyspneic” and the “non dyspneic” groups as defined by the mMRC scale with respect to BMI, ERV, FEV 1 and distance covered in 6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in obese subjects.

Abbreviations

BMI: Body Mass Index; mMRC scale: Modified Medical Research Council scale; 6MWT: Six-minute walk test; PFTs: Pulmonary function tests; FEV 1 : Expiratory volume in one second; VC: Vital capacity; FVC: Forced vital capacity; FRC: Functional residual capacity; ERV: Expiratory reserve volume; RV: Residual volume; TLC: Total lung capacity; DLCO: Carbon monoxide diffusing capacity of the lung; HbA1c: Glycated hemoglobin; NT pro-BNP: N-terminal pro brain natriuretic peptide; CRP: Serum C reactive protein.

Competing interests

None of the authors of the present manuscript have a commercial or other association that might pose a conflict of interest.

Authors’ contributions

CL, CB, EB, JN, JMP, SD, FL and GD conceived the study. CL acquired data. CB performed the statistical analysis. CL and GD drafted the manuscript. All authors read and approved the manuscript prior to submission.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2466/12/61/prepub

Acknowledgements

We thank the personnel of the Department of Nutrition and Pulmonary Medicine of the University Hospital of Reims for the selection and clinical/functional assessment of the patients.

• WHO. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/
• Sjöström L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karlsson J, Lapidus L. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord. 1992; 16 :465–479. [ PubMed ] [ Google Scholar ]
• Collet F, Mallart A, Bervar JF, Bautin N, Matran R, Pattou F, Romon M, Perez T. Physiologic correlates of dyspnea in patients with morbid obesity. Int J Obes (Lond) 2007; 31 :700–706. [ PubMed ] [ Google Scholar ]
• Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J Appl Physiol. 2010; 108 :206–211. doi: 10.1152/japplphysiol.00694.2009. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Gibson GJ. Obesity, respiratory function and breathlessness. Thorax. 2000; 55 (Suppl 1):S41–S44. [ PMC free article ] [ PubMed ] [ Google Scholar ]
• Ray CS, Sue DY, Bray G, Hansen JE, Wasserman K. Effects of obesity on respiratory function. Am Rev Respir Dis. 1983; 128 :501–506. [ PubMed ] [ Google Scholar ]
• Jones RL, Nzekwu M-MU. The effects of body mass index on lung volumes. Chest. 2006; 130 :827–833. doi: 10.1378/chest.130.3.827. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci. 1999; 318 :293–297. doi: 10.1097/00000441-199911000-00002. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Babb TG, Ranasinghe KG, Comeau LA, Semon TL, Schwartz B. Dyspnea on exertion in obese women: association with an increased oxygen cost of breathing. Am J Respir Crit Care Med. 2008; 178 :116–123. doi: 10.1164/rccm.200706-875OC. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Sahebjami H. Dyspnea in obese healthy men. Chest. 1998; 114 :1373–1377. doi: 10.1378/chest.114.5.1373. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Ofir D, Laveneziana P, Webb KA, O’Donnell DE. Ventilatory and perceptual responses to cycle exercise in obese women. J Appl Physiol. 2007; 102 :2217–2226. doi: 10.1152/japplphysiol.00898.2006. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Romagnoli I, Laveneziana P, Clini EM, Palange P, Valli G, de Blasio F, Gigliotti F, Scano G. Role of hyperinflation vs. deflation on dyspnoea in severely to extremely obese subjects. Acta Physiol (Oxf) 2008; 193 :393–402. doi: 10.1111/j.1748-1716.2008.01852.x. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Jensen D, Webb KA, Wolfe LA, O’Donnell DE. Effects of human pregnancy and advancing gestation on respiratory discomfort during exercise. Respir Physiol Neurobiol. 2007; 156 :85–93. doi: 10.1016/j.resp.2006.08.004. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Scano G, Stendardi L, Bruni GI. The respiratory muscles in eucapnic obesity: their role in dyspnea. Respir Med. 2009; 103 :1276–1285. doi: 10.1016/j.rmed.2009.03.023. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Ora J, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O’Donnell DE. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med. 2009; 180 :964–971. [ PubMed ] [ Google Scholar ]
• Sava F, Laviolette L, Bernard S, Breton M-J, Bourbeau J, Maltais F. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med. 2010; 10 :55. doi: 10.1186/1471-2466-10-55. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Lecube A, Sampol G, Muñoz X, Hernández C, Mesa J, Simó R. Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study. Diabetologia. 2010; 53 :1210–1216. doi: 10.1007/s00125-010-1700-5. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Lecube A, Sampol G, Muñoz X, Lloberes P, Hernández C, Simó R. Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study. Diabetes Metab Res Rev. 2010; 26 :639–645. doi: 10.1002/dmrr.1131. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, Guize L, Zureik M. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009; 179 :509–516. doi: 10.1164/rccm.200807-1195OC. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93 :580–586. doi: 10.1378/chest.93.3.580. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of Clinical Methods Used to Evaluate Dyspnea in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 1998; 158 :1185–1189. [ PubMed ] [ Google Scholar ]
• Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 36 :1067–1072. doi: 10.1183/09031936.00152609. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166 :111–117. [ PubMed ] [ Google Scholar ]
• Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16 :1–100. [ PubMed ] [ Google Scholar ]
• Eltayara L, Becklake MR, Volta CA, Milic-Emili J. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 154 :1726–1734. [ PubMed ] [ Google Scholar ]
• Gerlach Y, Williams MT, Coates AM. Weighing up the evidence-a systematic review of measures used for the sensation of breathlessness in obesity. Int J Obes. 2012. [ PubMed ]
• El-Gamal H, Khayat A, Shikora S, Unterborn JN. Relationship of dyspnea to respiratory drive and pulmonary function tests in obese patients before and after weight loss. Chest. 2005; 128 :3870–3874. doi: 10.1378/chest.128.6.3870. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984; 85 :751–758. doi: 10.1378/chest.85.6.751. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998; 113 :619–624. doi: 10.1378/chest.113.3.619. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J. 2006; 13 :203–210. [ PMC free article ] [ PubMed ] [ Google Scholar ]
• Sin DD, Jones RL, Man SFP. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med. 2002; 162 :1477–1481. doi: 10.1001/archinte.162.13.1477. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Beriault K, Carpentier AC, Gagnon C, Ménard J, Baillargeon J-P, Ardilouze J-L, Langlois M-F. Reproducibility of the 6-minute walk test in obese adults. Int J Sports Med. 2009; 30 :725–727. doi: 10.1055/s-0029-1231043. [ PubMed ] [ CrossRef ] [ Google Scholar ]
• Larsson UE, Reynisdottir S. The six-minute walk test in outpatients with obesity: reproducibility and known group validity. Physiother Res Int. 2008; 13 :84–93. doi: 10.1002/pri.398. [ PubMed ] [ CrossRef ] [ Google Scholar ]

• Journal home
• Advance online publication
• About the journal
• J-STAGE home
• Internal Medicine
• Volume 55 (2016) Issue 1
• Article overview

Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan Respiratory Medicine, Saiseikai Ohmuta Hospital, Japan

Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan

Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan Respiratory Medicine, Chikugo City Hospital, Japan

Corresponding author

2016 Volume 55 Issue 1 Pages 15-24

• Published: 2016 Received: November 11, 2014 Released on J-STAGE: January 01, 2016 Accepted: April 26, 2015 Advance online publication: - Revised: -

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

(compatible with BibDesk, LaTeX)

Objective The modified Medical Research Council (mMRC) scale is recommended for conducting assessments of dyspnea and disability and functions as an indicator of exacerbation. The aim of this study was to investigate whether the mMRC scale can be used to predict hospitalization and exacerbation in Japanese patients with chronic obstructive pulmonary disease (COPD). Methods In a previous 52-week prospective study, 123 patients with COPD were classified into five groups (grades 0 to 4) according to the mMRC scale and four groups (stages I to IV) according to the spirometric Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. The frequency and period until the first event of hospitalization and exacerbation were compared among the groups. Results The population of patients who experienced hospitalization and exacerbation during the 52-week study period, with an mMRC scale grade of 4, 3, 2, 1 and 0 was 50.0 and 100, 55.6 and 88.9, 21.1 and 73.7, 2.6 and 48.7, and 4.0 and 22.0%, respectively. A multivariate analysis adjusted for the GOLD stage and age showed that the patients with an mMRC scale grade of ≥3 had higher frequencies of hospitalization and exacerbation than those with lower grades. Meanwhile, the patients with an mMRC scale grade of ≥2 showed a significantly earlier time until the first exacerbation, but not hospitalization, in comparison with those with grade 0. Conclusion The present results indicate that, among Japanese patients with COPD, those with an mMRC scale grade of ≥3 have a significantly poorer prognosis and that the mMRC scale can be used to predict hospitalization and exacerbation.

• Add to favorites
• Additional info alert
• Citation alert
• Authentication alert

Japanese Journal of Medicine

Register with J-STAGE for free!

Already have an account? Sign in here

10 Day Weather - Astrakhan', RUS

• Top Stories More News
• Today's National Outlook
• Hurricane Tracker
• Snow & Ski Forecast
• Cold & Flu
• Allergy Forecast
• Fire Updates
• Traffic Cameras
• Weather Cameras
• Outdoor Sports Guide

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study

Affiliation.

• 1 Service des Maladies Respiratoires, INSERM UMRS 903, Hôpital Maison Blanche, CHU de Reims, Reims, Cedex, France. [email protected]
• PMID: 23025326
• PMCID: PMC3515513
• DOI: 10.1186/1471-2466-12-61

Background: Dyspnea is very frequent in obese subjects. However, its assessment is complex in clinical practice. The modified Medical Research Council scale (mMRC scale) is largely used in the assessment of dyspnea in chronic respiratory diseases, but has not been validated in obesity. The objectives of this study were to evaluate the use of the mMRC scale in the assessment of dyspnea in obese subjects and to analyze its relationships with the 6-minute walk test (6MWT), lung function and biological parameters.

Methods: Forty-five obese subjects (17 M/28 F, BMI: 43 ± 9 kg/m2) were included in this pilot study. Dyspnea in daily living was evaluated by the mMRC scale and exertional dyspnea was evaluated by the Borg scale after 6MWT. Pulmonary function tests included spirometry, plethysmography, diffusing capacity of carbon monoxide and arterial blood gases. Fasting blood glucose, total cholesterol, triglyceride, N-terminal pro brain natriuretic peptide, C-reactive protein and hemoglobin levels were analyzed.

Results: Eighty-four percent of patients had a mMRC ≥ 1 and 40% a mMRC ≥ 2. Compared to subjects with no dyspnea (mMRC = 0), a mMRC ≥ 1 was associated with a higher BMI (44 ± 9 vs 36 ± 5 kg/m2, p = 0.01), and a lower expiratory reserve volume (ERV) (50 ± 31 vs 91 ± 32%, p = 0.004), forced expiratory volume in one second (FEV1) (86 ± 17 vs 101 ± 16%, p = 0.04) and distance covered in 6MWT (401 ± 107 vs 524 ± 72 m, p = 0.007). A mMRC ≥ 2 was associated with a higher Borg score after the 6MWT (4.7 ± 2.5 vs 6.5 ± 1.5, p < 0.05).

Conclusion: This study confirms that dyspnea is very frequent in obese subjects. The differences between the "dyspneic" and the "non dyspneic" groups assessed by the mMRC scale for BMI, ERV, FEV1 and distance covered in 6MWT suggests that the mMRC scale might be an useful and easy-to-use tool to assess dyspnea in daily living in obese subjects.

PubMed Disclaimer

Similar articles

• Improvement of dyspnea after bariatric surgery is associated with increased Expiratory Reserve Volume: A prospective follow-up study of 45 patients. Boissière L, Perotin-Collard JM, Bertin E, Gaubil I, Diaz Cives A, Barbe C, Dury S, Nardi J, Lebargy F, Deslée G, Launois C. Boissière L, et al. PLoS One. 2017 Sep 20;12(9):e0185058. doi: 10.1371/journal.pone.0185058. eCollection 2017. PLoS One. 2017. PMID: 28931052 Free PMC article. Clinical Trial.
• Obesity Impact on Dyspnea in COPD Patients. Dupuis A, Thierry A, Perotin JM, Ancel J, Dormoy V, Dury S, Deslée G, Launois C. Dupuis A, et al. Int J Chron Obstruct Pulmon Dis. 2024 Jul 22;19:1695-1706. doi: 10.2147/COPD.S450366. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39070800 Free PMC article. Clinical Trial.
• Association between obesity-related dyspnea in daily living, lung function and body composition analyzed by DXA: a prospective study of 130 patients. Hagenburg J, Bertin E, Salmon JH, Thierry A, Perotin JM, Dormoy V, Dury S, Gaubil I, Bolko L, Lebargy F, Deslee G, Launois C. Hagenburg J, et al. BMC Pulm Med. 2022 Mar 25;22(1):103. doi: 10.1186/s12890-022-01884-5. BMC Pulm Med. 2022. PMID: 35337302 Free PMC article.
• Cardiopulmonary rehabilitation programme improves physical health and quality of life in post-COVID syndrome. Szarvas Z, Fekete M, Horvath R, Shimizu M, Tsuhiya F, Choi HE, Kup K, Fazekas-Pongor V, Pete KN, Cserjesi R, Bakos R, Gobel O, Kovacs O, Gyongyosi K, Pinter R, Kovats Z, Ungvari Z, Tarantini S, Horvath G, Muller V, Varga JT. Szarvas Z, et al. Ann Palliat Med. 2023 May;12(3):548-560. doi: 10.21037/apm-22-1143. Epub 2023 Mar 24. Ann Palliat Med. 2023. PMID: 37038060 Review.
• Obesity and lung function: a systematic review. Melo LC, Silva MA, Calles AC. Melo LC, et al. Einstein (Sao Paulo). 2014 Jan-Mar;12(1):120-5. doi: 10.1590/s1679-45082014rw2691. Einstein (Sao Paulo). 2014. PMID: 24728258 Free PMC article. Review.
• Association between healthy lifestyles and post-COVID-19 syndrome among college students. Sun D, Zhu X, Bao Z, Lin X. Sun D, et al. Ann Thorac Med. 2024 Apr-Jun;19(2):139-146. doi: 10.4103/atm.atm_219_23. Epub 2024 Apr 25. Ann Thorac Med. 2024. PMID: 38766372 Free PMC article.
• Development of a behavior change intervention to improve physical activity in patients with COPD using the behavior change wheel: a non-randomized trial. Xiang X, Han M, Luo X, Yu Y, Lu X, Cai S, Huang L. Xiang X, et al. Sci Rep. 2023 Dec 21;13(1):22929. doi: 10.1038/s41598-023-50099-z. Sci Rep. 2023. PMID: 38129630 Free PMC article. Clinical Trial.
• Which breathlessness dimensions associate most strongly with fatigue?-The population-based VASCOL study of elderly men. Cristea L, Olsson M, Sandberg J, Kochovska S, Currow D, Ekström M. Cristea L, et al. PLoS One. 2023 Dec 20;18(12):e0296016. doi: 10.1371/journal.pone.0296016. eCollection 2023. PLoS One. 2023. PMID: 38117831 Free PMC article.
• Impact of the COVID-19 Pandemic on Outcomes of CAPTURE: A Primary Care Chronic Obstructive Pulmonary Disease Screening Clinical Trial. Yawn BP, Make B, Mannino D, Lopez C, Murray S, Thomashow B, Brown R, Dolor RJ, Joo M, Tapp H, Zittleman L, Meldrum C, Anderson S, Martinez FJ, Han MK. Yawn BP, et al. Ann Am Thorac Soc. 2024 Jan;21(1):176-179. doi: 10.1513/AnnalsATS.202305-478RL. Ann Am Thorac Soc. 2024. PMID: 38099719 Free PMC article. No abstract available.
• Prediction value of neutrophil and eosinophil count at risk of COPD exacerbation. Chen TT, Lee KY, Chang JH, Chung CL, Tran HM, Manullang A, Ho SC, Chen KY, Tseng CH, Wu SM, Chuang HC. Chen TT, et al. Ann Med. 2023;55(2):2285924. doi: 10.1080/07853890.2023.2285924. Epub 2023 Dec 8. Ann Med. 2023. PMID: 38065676 Free PMC article.
• WHO. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/
• Sjöström L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karlsson J, Lapidus L. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord. 1992;16:465–479. - PubMed
• Collet F, Mallart A, Bervar JF, Bautin N, Matran R, Pattou F, Romon M, Perez T. Physiologic correlates of dyspnea in patients with morbid obesity. Int J Obes (Lond) 2007;31:700–706. - PubMed
• Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J Appl Physiol. 2010;108:206–211. doi: 10.1152/japplphysiol.00694.2009. - DOI - PubMed
• Gibson GJ. Obesity, respiratory function and breathlessness. Thorax. 2000;55(Suppl 1):S41–S44. - PMC - PubMed

Publication types

• Search in MeSH

Related information

Linkout - more resources, full text sources.

• BioMed Central
• Europe PubMed Central
• PubMed Central
• Genetic Alliance
• MedlinePlus Health Information

Research Materials

• NCI CPTC Antibody Characterization Program

• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.